

# SECURITIES & EXCHANGE COMMISSION EDGAR FILING

**Apollo Medical Holdings, Inc.**

**Form: 8-K**

**Date Filed: 2018-11-09**

Corporate Issuer CIK: 1083446

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d) OF  
THE SECURITIES EXCHANGE ACT OF 1934**

**Date of Report (date of earliest event reported): November 8, 2018**

**APOLLO MEDICAL HOLDINGS, INC.**

*(Exact name of registrant as specified in its charter)*

<b>Delaware</b>	<b>001-37392</b>	<b>46-3837784</b>
<i>(State or Other Jurisdiction of Incorporation)</i>	<i>(Commission File Number)</i>	<i>(I.R.S. Employer Identification Number)</i>

**1668 S. Garfield Avenue, 2nd Floor, Alhambra, CA 91801**

*(Address of principal executive offices) (zip code)*

**(626) 282-0288**

*(Registrant's telephone number including area code)*

**N/A**

*(Former name or former address, if changed since last report)*

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

---

---

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On November 8, 2018, Apollo Medical Holdings, Inc. (the "Company") was informed by Gary Augusta, a member of the Company's Board of Directors, that he has resigned as a director of the Company, effective November 8, 2018. Mr. Augusta has advised the Company that his resignation is not due to any dispute or disagreement with the Company.

---

## **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: November 9, 2018

**APOLLO MEDICAL HOLDINGS, INC.**

By: /s/ THOMAS S. LAM, M.D.

Name: Thomas S. Lam, M.D.

Title: Co-Chief Executive Officer